Perspectivas de tratamento e desafios na terapia antifúngica para a mucormicose em pacientes com COVID-19
DOI:
https://doi.org/10.33448/rsd-v14i3.48442Palavras-chave:
Infecções fúngicas, Agentes antifúngicos, Comorbidade, Gerenciamento clínico.Resumo
A pandemia da COVID-19 possibilitou o aumento de infecções oportunistas, como a exemplo da mucormicose, mais conhecido como “fungo negro”, em que sua prevalência se decorreu em várias partes do globo, especialmente na Índia. Tal infecção fúngica é altamente debilitante e apresenta altas taxas de morbidade e mortalidade, estando a terapia antifúngica voltada nos medicamentos antifúngicos convencionais com ou sem sucesso de tratamento. Diante disso, o objetivo deste trabalho foi identificar quais são as principais perspectivas e desafios provocados pelo tratamento antifúngico em pacientes que adquiriram a COVID-19 e consequentemente, a micose provocada por fungos da ordem Mucorales. Para isso, foi realizada um revisão integrativa da literatura a partir do planejamento de cinco etapas: elaboração da questão pesquisa (identificação do problema), busca dos estudos na literatura, avaliação dos estudos, análise dos dados e apresentação da revisão, do qual se utilizou da estratégia PICO. No decorrer da busca nas bases de dados, foram encontradas, incialmente 292 estudos (Science Direct=112, PubMed= 35, Scielo=1 e MEDLINE=144), que no final foram inclusos 38 estudos. Entre estudos, percebeu-se que há uma maior necessidade de diagnóstico precoce, bem como produção de manejo clínico intensivo, especialmente para pacientes que apresentam comorbidades; e também carece de uma produção de protocolos específicos para casos de mucormicose relacionados à COVID-19 com o intuito de melhorar os desfechos clínicos.
Referências
Abraham, A. M.; Mathew, G.; Thomas, S.; Nair, R.; & Kurian, B. (2024). Observational study on the clinical profile and treatment outcome on long-term follow-up of COVID-19 associated mucormycosis. Journal of Medical Mycology, p. 101491.
Alshahawey, M.; El-Housseiny, G. S.; Elsayed, N. S.; Alshahrani, M. Y.; EL-Wakeel, L. M.; & Aboshanab, K. M. (2022). New insights on mucormycosis and its association with the COVID-19 pandemic. Future Science OA, 8(2), FSO772.
Bayram, N.; Celikbaş, A. K.; Kaşka, B.; Gül, D.; Bozkurt, Y.; Düzenli, N.; & Erdöl, H. (2021). Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. Japanese Journal of Ophthalmology, 65(4), 515-525.
Chakravarty, J.; Kumar, A.; Singh, A.; Singh, R.; Yadav, R.; & Srivastava, V. (2022). COVID-19-associated mucormycosis: a clinico-epidemiological study. Journal of Diabetes and its Complications, 36(9), 108284.
Chakravarty, J.; Singh, S.; Raut, A.; Sharma, A.; Prasad, S.; Verma, N.; & Pandey, A. (2022). COVID-19-associated Mucormycosis: A clinico-epidemiological study. Journal of Diabetes and its Complications, 36(9), 108284.
Chandra, S.; Sharma, S.; Vats, R.; & Pandey, S. (2021). Isolated cerebral mucormycosis masquerading as a tumor in an immunocompetent patient. Autopsy and Case Reports, 11, e2020233.
Chao, C. ; Lai, C.; & Yu, W. (2022). COVID-19 associated mucormycosis–An emerging threat. Journal of Microbiology, Immunology and Infection, 55(2), 183-190.
Chatterjee, S.; Mondal, S.; Pal, R.; Sinha, P.; Ghosh, S.; & Roy, D. (2022). Pharmacovigilance study of amphotericin B for mucormycosis in post-COVID and non-COVID patients at a tertiary care hospital in Eastern India. Indian Journal of Pharmacology, 54(6), 417-422.
Dandu, H.; Sharma, V.; Singh, R.; Gupta, A.; Khandelwal, P.; Mehrotra, R.; & Kumar, A. (2024). Utility of Itraconazole in Combination with Liposomal Amphotericin B in Rhizopus oryzae Associated Mucormycosis–An Exploratory Study. Mycopathologia, 189(4), 54.
Dave, T. V.; Nair, A. G.; Homi, R.; Desai, S.; Gandhi, R. A.; Shukla, D.; Kalra, M. K.; & Mukherjee, B. (2021). Clinical presentations, management and outcomes of rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19: a multi-centric study. Ophthalmic Plastic & Reconstructive Surgery, 37(5), 488–495.
Dravid, A.; Saoji, R.; Bhalerao, M.; Gaikwad, P.; Doshi, R.; & Jog, S. (2022). Epidemiology, clinical presentation and management of COVID‐19 associated mucormycosis: A single centre experience from Pune, Western India. Mycoses, 65(5), 526-540.
Eshraghi, B.; Rahimi, M.; Amini, A.; Shirazi, M. T.; Nasiri, M.; Karimi, Z.; & Sadeghi, A. (2024). Risk Factors of COVID-19 associated mucormycosis in Iranian patients: a multicenter study. BMC Infectious Diseases, 24(1), 852.
Gandhi, A.; Kumar, A.; Gupta, N.; Sharma, P.; Yadav, H.; & Sharma, R. (2023). Battling the emerging epidemic of rhino-orbital-cerebral mucormycosis (ROCM) in COVID-19 pandemic: an interventional study. International Ophthalmology, 43(5), 1571–1580.
Ghelfenstein-Ferreira, T.; Serris, A.; Salmona, M.; Lanternier, F.; & Alanio, A. (2024). Revealing the hidden interplay: The unexplored relationship between fungi and viruses beyond HIV, SARS-CoV-2, and influenza. Medical Mycology, 62(4), myae021.
He, Q.; Liu, X.; Zhao, S.; Zhang, J.; Chen, S.; Li, M.; & Zhou, Yu. (2023). Efficacy and safety of glucocorticoids use in patients with COVID-19: a systematic review and network meta-analysis. BMC Infectious Diseases, 23(1), 896.
Hussain, M. K.; Khan, M. S.; Ahmad, I.; Shariq, A.; Singh, M.; Naeem, A.; & Khan, R. A. (2023). Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents. European Journal of Medicinal Chemistry, 246, 115010.
Jain, V.; Sharma, A.; Kapoor, S.; Gupta, P.; Kumar, A.; & Agrawal, R. (2023). Hit or Miss: The dilemma of specimen selection for microbiological diagnosis of rhino-orbital-cerebral-COVID-associated mucormycosis (ROCM-CAM). Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders), 23(1), 62-69.
Keshri, A.; Kumar, A.; Kumar, S.; Pandey, R.; & Singh, P. (2023). Is mucormycosis the end? A comprehensive management of orbit in COVID-associated rhino-orbital–cerebral mucormycosis: preserving the salvageable. European Archives of Oto-Rhino-Laryngology, 280(2), 819-827.
Khare, P.; Chaurasia, Y.; & Bhatnagar, S. (2022). Exploring the globe salvaging treatment options in patients of COVID-19-associated mucormycosis with orbital involvement. Indian Journal of Ophthalmology, 70(10), 3638-3642.
Kulkarni, R.; Misra, U. K.; Meshram, C.; Kochar, D.; Modi, M.; Vishnu, Venugopalan, Y.; Garg, R. K.; & Surya, N. (2022). Epidemic of mucormycosis in COVID-19 pandemic: a position paper. Annals of Indian Academy of Neurology, 25(1), 7–10.
Lockhart, Shawn R.; & Guarner, J. Emerging and reemerging fungal infections. (2019). In: Seminars in diagnostic pathology. WB Saunders. p. 177-181.
Madikonda, P. K.; Perugu, S. B.; & Ramadevi, C. H. (2022) Effect of Ayurvedic Intervention as an adjunct therapy in Post COVID-19 Mucormycosis (PCM): a non-randomized parallel group study. Journal of Ayurveda and Integrative Medicine, 13(4), 100672.
Madikonda, P. K.; Perugu, S. B.; & Ramadevi, C. H. (2022). Effect of Ayurvedic Intervention as an adjunct therapy in Post COVID-19 Mucormycosis (PCM): a non-randomized parallel group study. Journal of Ayurveda and Integrative Medicine, 13(4), 100672.
Manesh, A.; John, A. O.; Mathew, S. K.; Jayaseelan, V. P.; Thomas, P. P.; Karthik, R.; & Abraham, O. C. (2023). Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19-associated rhino-orbito-cerebral mucormycosis: a prospective cohort study. Clinical Microbiology and Infection, 29(10), 1298-1305.
Meher, R.; Kaushalya, B.; Khatri, I.; Khurana, N.; Panda, S.; Tripathy, A.; & Sahoo, N. (2022). COVID associated mucormycosis: a preliminary study from a dedicated COVID Hospital in Delhi. American Journal of Otolaryngology, 43(1), 103220.
Merchán-Hamann, E.; & Tauil, P. L. (2021). Proposta de classificação dos diferentes tipos de estudos epidemiológicos descritivos. Epidemiologia e Serviços de Saúde, 30, e2018126.
Mitra, S.; Janweja, M.; & Sengupta, A. (2021). Post-COVID-19 rhino-orbito-cerebral mucormycosis: a new addition to challenges in pandemic control. European Archives of Oto-Rhino-Laryngology, p. 1-6.
Mrig, S.; Ahuja, R.; Prasad, K. T. V.; Shukla, S.; Gupta, M.; Verma, A. K.; & Singh, D. (2022). Adjunctive use of saturated solution of potassium iodide (SSKI) with liposomal amphotericin B (L-AMB) in mucormycosis achieves favorable response, shortened dose and duration of amphotericin: A retrospective study from a COVID-19 tertiary care center. American Journal of Otolaryngology, 43(3), 103465.
Nagarkar, N. M.; Gupta, V.; Sharma, P.; Choubey, V.; Sharma, D.; & Jain, P. (2023). Mortality and its determinants after an outbreak of post COVID-19 associated rhino-orbito-cerebral mucormycosis in Central India. International Ophthalmology, 43(7), 2363-2370.
Nair, A. G.; Gupta, R.; Kumar, A.; Goel, M.; Goel, N.; & Rajan, J. (2021). Rhino-orbital mucormycosis following COVID-19 in previously non-diabetic, immunocompetent patients. Orbit, 40(6), 499-504.
Organização Mundial da Saúde. (s.d.). Mucormicose. https://www.who.int/india/home/emergencies/coronavirus-disease-(covid-19)/mucormycosis.
Pakdel, F.; Maleki, M.; Ahmadi, M.; Mokhtari, E.; Khoshdel, A. R.; Abbasi, H.; Jamali, S. H.; & Hashemi, S. J. (2021). Mucormycosis in patients with COVID‐19: a cross‐sectional descriptive multicentre study from Iran. Mycoses, 64(10), 1238-1252.
Patel, A.; Kothari, A.; Aggarwal, R.; Singh, A. K.; Das, S.; Saha, R.; Mukherjee, P.; & Mehra, S. (2021). Multicenter epidemiologic study of coronavirus disease–associated mucormycosis, India. Emerging Infectious Diseases, 27(9), 2349.
Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica. free e-book]. Editora UAB/NTE/UFSM, Brasil.
Prakash, Hariprasath; Chakrabarti, & Arunaloke. (2019). Global epidemiology of mucormycosis. Journal of Fungi, 5(1), 26.
Pulle, M. V.; Reddy, V.; Jain, R.; Kumar, A.; Singh, P.; Sharma, S.; & Gupta, K. (2023). COVID associated pulmonary mucormycosis: Outcomes of surgical therapy. Asian Cardiovascular and Thoracic Annals, 31(2), 133-141.
Raj, A.; Sharma, R.; Gupta, P.; Singh, N.; Chaudhary, V.; & Yadav, R. (2024). Survival benefit of exenteration in COVID-19-associated rhino-orbital mucormycosis. Indian Journal of Ophthalmology, 72(2), 190-194.
Rajendra Santosh, Ab; Muddana, K.; & Bakki, Sr. (2021). Fungal infections of oral cavity: diagnosis, management, and association with COVID-19. SN Comprehensive Clinical Medicine, 3(6), 1373–1384.
Ramaswami, A.; Srivastava, S.; Shankar, S.; Sarin, Y. K.; Gupta, S.; Pandey, P.; & Singh, V. (2021). COVID-19-associated mucormycosis presenting to the Emergency Department—an observational study of 70 patients. QJM: An International Journal of Medicine, 114(7), 464-470.
Ravani, S. A.; Agarwal, D.; Gupta, M.; Gupta, S.; Rakheja, V.; Kadwani, H.; & Goyal, S. (2021). Rise of the phoenix: Mucormycosis in COVID-19 times. Indian Journal of Ophthalmology, 69(6), 1563-1568.
Sahu, M.; Maji, A.; Panda, S.; Das, S.; Roy, S.; Mahakur, B.; & Parida, P. K. (2023). COVID-19 associated multisystemic mucormycosis from India: a multicentric retrospective study on clinical profile, predisposing factors, cumulative mortality and factors affecting outcome. Infection, 51(2), 407-416.
Schwarz, P.; Cornely, O. A. & Dannaoui, E. (2019). Antifungal combinations in Mucorales: a microbiological perspective. Mycoses, 62(9), 746–760.
Selarka, L.; Chauhan, Z.; Shah, M.; Trivedi, M.; Patel, S.; Sheth, R. & Shah, M. (2021). Mucormycosis and COVID‐19: an epidemic within a pandemic in India. Mycoses, 64(10), 1253-1260.
Shaikh, Z.; Khan, S.; Patil, M.; Desai, R. & Joshi, A. (2023). To evaluate the efficacy of topical anti-fungal therapy in postoperative cases of COVID Associated Mucormycosis (CAM): A single-blinded randomized control trial. American Journal of Otolaryngology, 44(2), 103702.
Shakrawal, J.; Agarwal, A.; Sharma, S.; Khandelwal, A.; Singh, V. & Verma, S. (2023). Outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19. International Ophthalmology, 43(6), 1919-1926.
Sharma, A. & Goel, A. (2022). Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic. Folia Microbiologica, 67(3), 363–387.
Sharma, S.; Grover, M.; Bhargava, S.; Samdhani, S. & Kotwal, A. (2021). Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. The Journal of Laryngology & Otology, 135(5), 442-447.
Shen, M.; Li, J.; Zhang, Y.; Wang, X.; Zhou, Y. & Chen, H. (2023). The outcome and the risk factors of mucormycosis among patients with hematological diseases: A systematic and meta-analysis. Frontiers in Medicine, 10, 1268840.
Smith, C. & Lee, S. C. (2022). Current treatments against mucormycosis and future directions. PLoS Pathogens, 18(10), e1010858.
Snyder, Hannah (2019). Literature review as a research methodology: An overview and guidelines. Journal of business research, 104, 333-339.
Soman, R.; Chakraborty, S. & Joe, G. (2022). Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis: A retrospective observational case series. International Journal of Infectious Diseases, 120, 177-178.
Soni, K.; Agarwal, A.; Singh, P.; Verma, A.; Pandey, R. & Shukla, R. (2022). Surgical & medical management of ROCM (Rhino-orbito-cerebral mucormycosis) epidemic in COVID-19 era and its outcomes – A tertiary care center experience. Journal of Medical Mycology, 32(2), 101238.
Tashiro, M.; Hayakawa, J.; Wakatsuki, H.; Kasai, D.; Tanaka, Reiko; Takashima, A.; Kohno, S. & Matsumoto, T. (2023). Prognostic association of liposomal amphotericin B doses above 5 mg/kg/d in mucormycosis: a nationwide epidemiologic and treatment analysis in Japan. In: Open Forum Infectious Diseases. US: Oxford University Press. p. ofad480.
Vare, A. A.; Mundhe, S. A.; Ghanvate, S. A.; Jadhav, S. P. & Shetty, V. P. (2021). Incidence, cumulative mortality and factors affecting the outcome of COVID-19-associated mucormycosis from Western India. Indian Journal of Ophthalmology, 69(12), 3678-3683.
Vijayasekhar, M. V.; Sharma, P.; Reddy, K. S.; Kumar, P. & Kumar, N. (2022). Post-covid cerebral mucormycosis, varied presentations and surgical strategies of a newer epidemic: an institutional experience. Neurology India, 70(3), 1052-1056.
Whittemore, R. & Knafl, K. (2005). The integrative review: updated methodology. Journal of advanced nursing, 52(5), 546-553.
Yadav, D. S.; Jain, A.; Sharma, P.; Agarwal, A.; Singh, R.; Meena, M. & Bhati, P. (2023). Coronavirus Disease-19-associated Mucormycosis: A Single-center Observational Study of 69 Patients. The Journal of the Association of Physicians of India, 72(10), 24-31, 2023.
Yadav, H.; Aggarwal, S.; Kaushik, G.; Sharma, R.; Singh, A.; Garg, D. & Mahajan, M. (2022). Analysis of COVID-19-associated rhino-orbital-cerebral mucormycosis patients in a tertiary care center in Northern India. Indian Journal of Ophthalmology, 70(6), 2163–2168.
Yadav, R.; Singh, A.; Mittal, S.; Khanna, R. C.; Singh, S.; Anupurath, S. & Singh, N. (2022). Corneal manifestations and treatment among patients with COVID-19-associated rhino-orbito-cerebral mucormycosis. Indian Journal of Ophthalmology, 71(1), 101-108.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2025 Franciele Maiara de Araújo Castro; Francisca Karolina de Luna Souto; Paula Raquel Ribeiro Silva; Igara Oliveira Lima; Wylly Araújo de Oliveira
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
